- Home
- MRLN vs UNCY Comparison
MRLN vs UNCY Comparison
Compare MRLN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | UNCY |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 150.1M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRLN | UNCY |
|---|---|---|
| Price | $1.55 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $8.58 | ★ $28.40 |
| AVG Volume (30 Days) | ★ 3.2M | 833.9K |
| Earning Date | 11-15-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $9.23 | N/A |
| Revenue Next Year | $153.29 | $10,812.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $3.93 |
| 52 Week High | $17.00 | $8.74 |
Technical Indicators
Market Signals| Indicator | MRLN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 30.15 |
| Support Level | N/A | $3.93 |
| Resistance Level | $3.45 | $5.86 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 1.08 | 7.06 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc develops software that fulfills the functions of a human pilot in self-flying aircraft to enable both reduced crew and unmanned flight. This technology is designed to be scalable and adaptable across different aircraft types for a growing range of aircraft platforms. The company's aircraft-agnostic, AI-powered software is purpose-built for military and civil programs, and is powering an expanding range of missions and aircraft, through hundreds of autonomous flights from test facilities across the globe. It operates as a single operating and reportable segment.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.